SCHEMBL2926593

SCHEMBL2926593

CC1CCC(C)N1Cc1ccc2cc(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)ccc2n1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.71
HTR2C P28335 6/20 0.71
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
PTPN1 P18031 1/20 0.45
HTR1A P08908 3/20 0.45
HTR1B P28222 3/20 0.45
HTR1F P30939 3/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ADORA2A P29274 1/20 0.44
POLB P06746 1/20 0.44
HTR1D P28221 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925938 0.96 MCHR1 (0.72) MCHR1HTR2CMAPTMEN1KMT2A
SCHEMBL2921993 0.91 MCHR1 (0.59) MCHR1HTR2CMAPTMEN1KMT2A
SCHEMBL2925011 0.90 MCHR1 (0.58) MCHR1HTR2CMAPTMEN1KMT2A
SCHEMBL2928051 0.88 MCHR1 (0.59) MCHR1HTR2CNPC1RAB9A
SCHEMBL2925595 0.88 MCHR1 (0.59) MCHR1HTR2CMEN1KMT2AKDM4E
SCHEMBL13177410 0.87 MCHR1 (0.58) MCHR1HTR2CMEN1KMT2AALDH1A1
SCHEMBL2926363 0.87 MCHR1 (0.58) MCHR1HTR2CMEN1KMT2AALDH1A1
SCHEMBL2926531 0.85 MCHR1 (0.57) MCHR1HTR2CMAPTALDH1A1LMNA
SCHEMBL2927594 0.83 MCHR1 (1.00) MCHR1HTR2CMAPTMEN1KMT2A
SCHEMBL2926869 0.82 MCHR1 (0.98) MCHR1HTR2CMAPTADORA2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885MAPT 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.